Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALERIA: Rivaroxaban vs Enoxaparin for VTE Prophylaxis
NCT04999176Phase 3Unknown
- Start
- Oct 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms). Primary endpoint: Venous thromboembolism and VTE related-death at Day 30. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04999176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999176.